IL-31 Monoclonal Antibody (31SNEZE), eFluor™ 660, eBioscience™, Invitrogen™

Description

Description: This 31SNEZE monoclonal antibody reacts with human IL-31. Interleukin-31 (IL-31) is a recently-discovered member of the IL-6 family of cytokines. It is expressed by CD4+ T cells, particularly those with a Th2 phenotype, and mast cells. The IL-31 receptor is a heterodimer composed of one IL-31RA and one OSMR beta subunit. This receptor is constitutively expressed by various cells types, including macrophages, monocytes, eosinophils, keratinocytes, and epithelial cells. IL-31 receptor signaling leads to STAT3 activation and promotes the release of proinflammatory cytokines and chemokines, such as IL-1 beta, IL-6, IL-8, CXCL1, and CCL2. Over-expression of IL-31 is observed in patients with allergic asthma, allergic rhinitis, and atopic dermatitis, with a positive correlation between circulating levels and disease severity. Applications Reported: This 31SNEZE antibody has been reported for use in intracellular staining followed by flow cytometric analysis. Applications Tested: This 31SNEZE antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis of human peripheral blood lymphocytes. This can be used at 5 μL (0.125 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells. IL-31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor. In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways. RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells. IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL-31 may represent a novel target for antipruritic drug development.